Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922389 | 0.81 | HTR2A (0.40) | PDE10AHTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL21767378 | 0.81 | PDE10A (0.42) | PDE10AHTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL21767388 | 0.81 | PDE10A (0.42) | PDE10AHTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL21767380 | 0.81 | PDE10A (0.42) | PDE10AHTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL31072001 | 0.81 | PDE10A (0.42) | PDE10AHTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL19056900 | 0.77 | CCR1 (0.42) | PDE10AHTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL16668842 | 0.74 | PDE10A (0.38) | PDE10A | |
| SCHEMBL20153763 | 0.74 | PDE10A (0.54) | PDE10AHTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4068530 | 0.74 | PDE10A (0.34) | PDE10A | |
| SCHEMBL7556092 | 0.72 | PDE10A (0.52) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2925762-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Sunovion Pharmaceuticals Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-2049490-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885HTR2A 24/4885HTR2C 16/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | PDE10A 2029/4885HTR2A 1003/4885HTR2C 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.